Artificial intelligence stands at the center of our vision for precision medicine. We are developing multimodal AI platforms that integrate imaging, clinical parameters, and longitudinal outcomes to advance individualized patient care. By leveraging deep learning, radiomics, and advanced data fusion techniques, we aim to refine diagnosis, enhance risk prediction, and support clinical decision-making across a broad spectrum of women\u2019s health conditions. Our work focuses on creating interpretable, clinically deployable AI tools that improve treatment planning, forecast therapeutic response, and ultimately elevate the quality and equity of care delivered to diverse patient populations.<\/p>\n
Our lab is pioneering next-generation imaging technologies with the potential to reshape both diagnostic and interventional practice. Our team is expanding the clinical utility of contrast-enhanced ultrasound, exploring its advantages as a radiation-free, real-time, and highly sensitive tool for evaluating vascularity, soft tissue disease, and treatment response. In parallel, we are advancing MRI-based innovations\u2014including functional and quantitative imaging protocols\u2014that provide unprecedented detail for assessing complex benign and high-risk conditions in women. Through rigorous technical development and clinical validation, we aim to bring novel imaging strategies into routine practice, ensuring earlier detection, more accurate characterization, and improved procedural guidance.<\/p>\n
Uterine fibroids represent one of the most prevalent and burdensome gynecologic conditions affecting women of reproductive age. Our research is dedicated to transforming the management of fibroids by advancing non-surgical, image-guided therapies such as uterine artery embolization (UAE) and MRI-guided focused ultrasound surgery (MRgFUS). We are optimizing multimodal imaging techniques\u2014particularly MRI, contrast-enhanced ultrasound, and quantitative mapping\u2014to improve patient selection, refine procedural planning, and enhance post-treatment assessment. In addition, our team is identifying biomarkers, radiomic signatures, and imaging-based predictors of therapeutic success to support personalized treatment pathways. By integrating technological innovation with rigorous clinical investigation, we aim to expand minimally invasive options, improve quality of life, and reduce health disparities for women affected by fibroids.<\/p>\n
Placental disorders, including placenta accreta spectrum (PAS) and placenta previa, pose profound risks during pregnancy and remain a leading cause of maternal morbidity. Our lab is advancing high-resolution imaging approaches\u2014such as targeted MRI protocols, diffusion techniques, and contrast-enhanced ultrasound\u2014to enhance early detection, improve risk stratification, and guide multidisciplinary perinatal planning. Beyond diagnosis, we are exploring innovative image-guided interventions to optimize delivery outcomes. Our research seeks to redefine clinical pathways for high-risk pregnancies by improving diagnostic precision, enhancing safety, and enabling more predictable management for both mother and child.<\/p>\n
Peripheral vascular disease (PAD) in women remains underrecognized and frequently undertreated, in part due to sex-specific differences in presentation, vessel size, and disease progression. Our research aims to close this gap by developing advanced imaging frameworks to improve early identification and nuanced risk assessment in women. We are also evaluating minimally invasive therapeutic options, including drug-eluting technologies, targeted atherectomy, vessel-prep strategies, and precision catheter-based interventions tailored to female vascular anatomy and disease patterns. Through this work, our lab is driving a more personalized and equitable approach to vascular care, with the ultimate goal of improving functional outcomes and long-term cardiovascular health for women at risk of PAD.<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"